profit from every $100 of sales.
$0$100
Eikon Therapeutics
$6.67+8.81% today
-55.5% since Feb 5, 26
1-year low $5.311-year high $16.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Eikon Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2025, with -$324 million of profit last year.
SalesProfit
Eikon Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Eikon Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Eikon Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 0 | |
| – | – | – | |
| -266 | -260 | -339 | |
| -224 | -218 | -299 | |
| -242 | -244 | -324 | |
| -7.40 | -7.45 | -6.18 | |
| – | – | – | |
| – | – | – | |
| – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 526 | 491 | 595 |
| Cash | 113 | 129 | 105 |
| Total debt | 32 | 202 | 257 |
| Total liabilities | 867 | 1,063 | 1,474 |
| -341 | -572 | -879 | |
| 33 | 33 | 54 | |
| – | – | – | |
| 70.9% | 42.6% | 36.9% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -191 | -135 | -189 | |
| 29 | 85 | 47 | |
| -219 | -220 | -235 | |
| Dividends paid | – | – | – |
| – | – | – | |
| 10 | 12 | 18 |
Valuation
- –
- –
- –
- 1.1×
- –
- –
- –
- -65.1%
- -89.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -20.9%
- 52.2%
- 43.1%
- -19.1%
- -21.2%
- –
Growth
- –
- –
- –
- –
- –
Financial health
- -0.6×
- 0.46
- 30.0%
- –
- 11.75
- 11.75
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 958
Bottom 21%of 888
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -2.46 | -1.98 | −24.4% |
| Mar 30, 2026 | -27.00 | -3.56 | −658.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
65Pass
Philip Fisher
49No pass
Peter Lynch
54No pass
Joel Greenblatt
2No pass
Charlie Munger
48No pass
Terry Smith
48No pass
Questions about Eikon Therapeutics
Is Eikon Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Eikon Therapeutics AI analysis
What does Eikon Therapeutics do?
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. It is in Biotechnology.
Does Eikon Therapeutics pay a dividend?
No. Eikon Therapeutics does not pay a dividend at the moment.
Is Eikon Therapeutics stock halal?
No. Eikon Therapeutics does not pass our halal screen: its debt is 71% of its market value, at or above the 33% limit. How we check
Who are Eikon Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Eikon Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.